about
Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver diseaseThe ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sexEvidence for concurrent effects of exposure to environmental cadmium and lead on hepatic CYP2A6 phenotype and renal function biomarkers in nonsmokers.Is there evidence for potential harm of electronic cigarette use in pregnancy?Interpatient variability in dexmedetomidine response: a survey of the literatureDrug Metabolism - From In Vitro to In Vivo, From Simple to Complex: Reflections of the BCPT Nordic Prize 2014 AwardeeIn utero tobacco exposure epigenetically modifies placental CYP1A1 expressionData mining of public SNP databases for the selection of intragenic SNPs.Tumoral expression of drug and xenobiotic metabolizing enzymes in breast cancer patients of different ethnicities with implications to personalized medicine.Pharmacogenetics of the major polymorphic metabolizing enzymes.Human pharmacogenomic variations and their implications for antifungal efficacy.Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo.A review and assessment of potential sources of ethnic differences in drug responsiveness.The four Ds deconstructed.Pharmacogenomics of maternal tobacco use: metabolic gene polymorphisms and risk of adverse pregnancy outcomes.Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes.Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.Genetics and drug use as a complex phenotype.Drug bioactivation, covalent binding to target proteins and toxicity relevance.CYP2A6 polymorphisms: is there a role for pharmacogenomics in preventing coumarin-induced hepatotoxicity in lymphedema patients?In vivo modulation of the behavioral effects of nicotine by the coumarins xanthotoxin, bergapten, and umbelliferoneGenetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of lung cancerAn overview of interactions between micronutrients and of micronutrients with drugs, genes and immune mechanisms.A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity.Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity.Inhibitory potency of 8-methoxypsoralen on cytochrome P450 2A6 (CYP2A6) allelic variants CYP2A6 15, CYP2A6 16, CYP2A6 21 and CYP2A6 22: differential susceptibility due to different sequence locations of the mutations.In vitro modulation of naturally occurring flavonoids on cytochrome P450 2A6 (CYP2A6) activity.More potent inhibition of human CYP2A6 than mouse CYP2A5 enzyme activities by derivatives of phenylethylamine and benzaldehyde.Nicotine gum or patch treatment for smoking cessation and smoking reduction: a multi-centre study in Chinese physicians.Lympidem (a coumarin derivative) induced reversible hepatotoxicity in an adult Sri Lankan.Nicotine metabolism and urinary elimination in mouse: in vitro and in vivo.Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme--an in silico approach.Saliva cotinine and exhaled carbon monoxide levels in natural environment waterpipe smokers.Metabolism of α-thujone in human hepatic preparations in vitro.Pregnancy and pharmacogenomics in the context of drug metabolism and response.
P2860
Q24319917-8FCC4252-8B6D-4CB0-BF4A-D7D2006EA51CQ24595571-37EF0427-D3AF-4A9E-8639-A1AA7497CBF0Q24816188-C3C2D8F2-CB73-47F3-A526-3BBFC86F7BE6Q26830532-AE8BD257-8AF3-4FE5-BDBD-627BAC4DC51AQ26994769-99FF8675-8987-41D2-836D-1EC7317F024BQ28083049-76CE56AA-44DE-44AB-8385-E252A0C7AF31Q28749684-B6D935FC-D70E-4C69-8BBC-524AA6BBBBAEQ30717630-7497D699-C6D6-4B38-AF33-534B9A266C88Q33881477-F7242596-8F71-4648-BF2E-667001C63426Q35067187-4F2CF90F-0A27-47B7-BAEF-9D20551A9628Q35070838-AAF93894-DF75-415C-AE27-885D102D1E73Q35130543-39E2835B-18A1-485B-B523-FF28BE76B444Q35217493-64DAFA80-7AFE-49ED-ABD4-83B25DCA6441Q35620282-01A314D3-2DDC-4424-B172-A35ADA18BB83Q35686844-30CBF222-1977-4B5D-A72C-9E1863564843Q35873687-958BBAB0-297D-4264-B361-757A92C2A910Q35876954-C46EA5B1-1400-4FD1-9D54-6AC3A0B3226CQ35978336-FAACFB92-D2DD-4FD7-986F-24FD01C21E97Q36061821-61BE0824-3100-444F-8FA5-DD1667A554CFQ36730627-68352A0D-CE90-4D4C-9A27-094D34128E16Q36918424-8292BA7A-F301-41D3-90DA-11714281919BQ37296120-550F02E7-0BF8-4902-BAF0-AE6787A9BF28Q37350081-D576FE6F-BE2F-4AF3-9D28-746DAFDF7E51Q40587899-FAD622A7-B714-45EF-BB4F-DAC3936D33A8Q40701329-AF40D960-370A-4864-9656-24F264758121Q41893942-AA15AD23-D8C0-4228-B6AC-ABC4FB7C57A1Q43093974-3785CF0B-17D3-439B-8D70-2196636BB993Q44440357-9A5C78F0-A965-4EA7-9C9D-CA598FD39B6DQ45144674-D706B5DC-DD4B-49D7-BF47-C65A5F7E4F1DQ46057111-57E4D9E3-C64B-4757-8540-F88E38714CBBQ46837480-B3F50747-3A75-48FF-AD9C-B6E20A0154D2Q46960266-0EFB49AD-CEAF-4931-895F-332A145222FAQ50961456-B878A651-C0BC-4BF0-9C3D-F02F921D0004Q53751124-2311424B-52AC-4289-8C8A-8BA61618580CQ54659609-D2495B22-DCC7-41ED-A5EA-00DADB56910A
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Polymorphisms of CYP2A6 and its practical consequences
@ast
Polymorphisms of CYP2A6 and its practical consequences
@en
Polymorphisms of CYP2A6 and its practical consequences
@nl
type
label
Polymorphisms of CYP2A6 and its practical consequences
@ast
Polymorphisms of CYP2A6 and its practical consequences
@en
Polymorphisms of CYP2A6 and its practical consequences
@nl
prefLabel
Polymorphisms of CYP2A6 and its practical consequences
@ast
Polymorphisms of CYP2A6 and its practical consequences
@en
Polymorphisms of CYP2A6 and its practical consequences
@nl
P2093
P2860
P3181
P1476
Polymorphisms of CYP2A6 and its practical consequences
@en
P2093
P2860
P304
P3181
P356
10.1046/J.0306-5251.2001.01500.X
P407
P577
2001-10-01T00:00:00Z